17 September 2018 Cambridge, UK, 17 September 2018: Sphere Fluidics, a company commercializing single cell analysis systems underpinned by its patented picodroplet technology, today introduced Cyto-Mine® Studio Software Suite, an updated software for its innovative Cyto-Mine Single Cell Analysis System. The software works alongside industry-standard robotic platforms and corporate databases to improve antibody discovery and cell line development workflows.Sphere Fluidics’ Cyto-Mine is an automated platform which integrates single cell screening, sorting, isolation and clone verification. Its…

13 September 2018     Draft Coverage Supports the Use of InVisionFirst-Lung for Aiding in the Management of Patients with Advanced Non-Small-Cell Lung Cancer   Research Triangle Park, NC and Cambridge, UK, September 13, 2018 -- Inivata, a leader in liquid biopsy, today announces that Palmetto GBA, a Medicare Administrative Contractor that  evaluates diagnostic technology through its laboratory technology assessment group, MolDx, has published a draft local coverage determination (LCD) for the InVisionFirst-Lung test. The draft LCD recommends coverage for InVisionFirst-Lung…

12 September 2018 Michelle Gale joins as Head of Customer Services, Dr Ben Cliff as Vice President of Operations, and Lorraine Bater as Regional Director of the South, UK  Appointments support provision of routine testing, monitoring and specialist analysis services to life sciences, food & consumer services, and industrial and environmental services industries Manchester, UK, 12 September 2018: Concept Life Sciences (Concept), the integrated drug discovery, development and analytical services company, today announced it has made three senior appointments to its Analytical Services…

Babraham 10 September 2018: The Babraham Research Campus is delighted to announce Taylor Vinters and Silicon Valley Bank as the latest organisations to pledge support for the Babraham Research Campus’ life-science accelerator, Accelerate@Babraham.Designed to support the earliest stages of new life-science ventures, via the provision of easy-access laboratory and office space together with supporting programmes of business, science, finance and entrepreneurial mentoring, Accelerate@Babraham’s inaugural programme starts later this month. Six companies are enrolled on the programme, five of…

The successfully defended patent protects novel compositions of a specific type and group of vaccines, called polysaccharide vaccines. Examples of polysaccharide vaccines are vaccines that are used to protect against Meningitis or Pneumonia. Such products are known to degrade over time, leading to gradual loss of potency. The novel compositions protected by this patent prevent such degradation and enable the development of improved polysaccharide vaccines in more convenient dosage forms that can be used outside the cold chain, thereby increasing the efficiency of immunisation coverage.Arecor’…

$133 Million Deal Adds European Early Development Center of Excellence to Global NetworkSOMERSET, N.J., July 3, 2018 – Catalent, Inc. (NYSE: CTLT), the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced that it has agreed to acquire Juniper Pharmaceuticals, Inc. (NASDAQ: JNPR), including its Nottingham, U.K.-based Juniper Pharma Services division. When combined with Catalent’s existing industry-leading drug development and manufacturing capabilities in the U.S. and Europe, the acquisition of…

CAMBRIDGE, UK, 02 July 2018 – EVONETIX LTD (‘Evonetix’), the Cambridge-based company pioneering an innovative approach to enable scalable and high-fidelity gene synthesis, announced today that it had been awarded substantial funding to support the development of a novel enzymatic approach to DNA synthesis. Innovate UK, the UK’s innovation agency, will co-fund the £1.3 million project, which will be undertaken in collaboration with Durham University. Evonetix is revolutionising gene synthesis with the aim of producing DNA at scale to facilitate many applications in the rapidly growing field of…

Attributes ongoing success to scientific ethos, project management, and innovative research programs.Cambridge, UK, 02 July 2018: IONTAS Limited (IONTAS), a leader in the discovery and optimisation of fully human antibodies, is celebrating its fifth anniversary. To mark the occasion, the Company held an anniversary party at King’s College, Cambridge, on 30th June 2018, with drinks, dinner and live music.  The Company was founded, without external investment, in 2013, by Dr John McCafferty, now CEO at IONTAS, in his laboratories within the biochemistry department of the University of…

NESDEP portable laboratory for pathogen detection is now being transferred for manufacture NESDEP detects pathogens in less than 90 minutes, and aims to provide significant cost savings whilst reducing the incidence of foodborne illnesses Cambridge, UK, 02 July 2018: TTP Plc (TTP), a leading independent technology and product development company, and Cubed Laboratories (Cubed), a developer of rapid, DNA-based molecular diagnostic devices and test kits, today announced the successful completion of a project to develop Cubed’s core product, the NESDEP portable laboratory for pathogen…